Join Emily McInturf and Andrei Seryi at SCOPE Europe 2026
Emily McInturf, Director, Feasibility, and Andrei Seryi, Director, Knowledge Management, are speaking on AI-driven site selection at SCOPE Europe 2026. Meet the PSI CRO team afterward to discuss improving enrollment forecasting and site fit visibility before study startup.
Eliminating Blind Spots in Site Selection with an AI Knowledge Platform
13 Oct., 2026 · 9:40 AM · Feasibility & Site Selection track
Learn how sponsors can identify enrollment risks earlier by applying NLP, semantic knowledge graphs, and AI-assisted reasoning to protocol-to-site fit analysis.
Industry data shows that 37% of clinical trial sites under-enroll and 11% enroll no patients at all – a persistent source of startup delays and enrollment disruption. At SCOPE Europe 2026, PSI will demonstrate how its AI-enabled semantic knowledge platform generates ranked site options and surfaces enrollment risks before startup decisions are locked in.
PSI’s feasibility infrastructure supports a 97% last-patient-in on-time rate across 58 countries. PSI’s proprietary INTELIA™ platform, recognized with the Frost & Sullivan 2025 Best Practices Award, enables sponsors to model and compare hundreds of country and site combinations while evaluating enrollment probability, operational fit, and budget alignment.
For more details, please visit this webpage.
Attending team members:
- Andrei Seryi
Senior Director, Business Development - Emily McInturf
Senior Director, Business Development & Team Lead - Kasia Moscicka
Global Head, Feasibility
Related resources:
Blog: The site economy: Understanding site decision-making
Webinar: Agentic AI in Clinical Trials — Swiss Biotech Day Panel
White Paper: The operational reality of agentic AI in phase 2-3 trials
